Vertex Pharmaceuticals is seeking a court declaration from the US Department of Health and Human Services that its offer of fertility preservation services offered alongside its gene editing therapy for sickle cell disease and beta-thalassemia, does not violate federal anti-kickback laws.
Reuters reported that the company had been offering financial support for fertility preservation services to patients receiving Casgevy, as this is not covered by Medicaid.
